Lindsay A. Rosenwald, M.D. – Executive Chairman
Dr. Rosenwald has almost 25 years of experience as a biotechnology entrepreneur, including the founding and recapitalization of numerous public and private biotechnology and life sciences companies. In addition to serving as Caelum’s Executive Chairman, Dr. Rosenwald is Chairman, President and CEO of Fortress Biotech, Caelum’s parent company. Dr. Rosenwald is also a Co-Portfolio Manager and Partner at Opus Point Partners Management, LLC, a life-science focused asset management firm. Before moving into his current positions, Dr. Rosenwald served as Chairman of Paramount BioCapital, Inc. Dr. Rosenwald received an M.D. from Temple University School of Medicine and a B.S. in finance from Pennsylvania State University.

Michael Weiss – Director
Mr. Weiss is a member of Caelum’s Board of Directors and Executive Vice Chairman, Strategic Development, of Caelum’s parent company, Fortress Biotech, where he also serves as Co-Vice Chairman of its Board of Directors. In addition to his roles at Fortress, Mr. Weiss is Executive Chairman, President and CEO of TG Therapeutics, Inc. (NASDAQ: TGTX), a publicly traded biotechnology company that he co-founded in 2011, and is Co-Portfolio Manager and Partner at Opus Point Partners Management, LLC. Previously, Mr. Weiss was Chairman and CEO of Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), where he led efforts to acquire and develop its lead drug Zerenex, and executed a $100M+ strategic alliance for Zerenex with JT Tobacco, Inc., and Torii Pharmaceutical Co., Ltd. Mr. Weiss began his career as a lawyer at Cravath, Swaine & Moore LLP in New York City. He earned a J.D. from Columbia University Law School and a B.S. in finance from The State University of New York at Albany.

Michael Spector – President and Chief Executive Officer and Director
Mr. Spector was named President and Chief Executive Officer as well as a member of the board of directors of Caelum in January 2017. He joins Caelum from Fortress Biotech, where he leveraged more than 25 years of biotechnology experience to identify emerging and innovative technologies to launch as new biotech and specialty pharmaceutical companies. Prior to Fortress, Mr. Spector served as Senior Vice President, Global Commercial Operations at Iroko Pharmaceuticals. Earlier in his career, he spent 15 years at GlaxoSmithKline in multiple senior management positions, including Vice President and General Manager of GlaxoSmithKline South Africa, where he led the overall business strategy and was elected to run the South African Pharmaceutical Manufacturers Association. Mr. Spector is also a founding member of Windhoek Healthcare, where he launched two specialty pharmaceutical companies: Laurel Pharmaceuticals and North Creek Pharmaceuticals. Mr. Spector holds an M.B.A. from Rider University in Lawrenceville, N.J., where he serves on the Business and Scientific Advisory Boards, and a B.S. in biology from the University of Pittsburgh. He also serves on the Board of Directors of Jacaranda Health, a nonprofit organization that seeks to transform maternal and neonatal healthcare in East Africa.

Kenneth W. Cappell – Director
Mr. Cappell began serving on our Board in June 2017. He is currently a Director of Arotech Corporation and has been an Adjunct Professor of Accounting at Baruch College since Fall of 2015.  For the 2014-2015 academic year, he served as an Adjunct Professor of Accounting at Yeshiva University. From 1987 until 2014, Mr. Cappell was a partner of PricewaterhouseCoopers LLP (“PwC”) and its predecessor firms, first as an audit partner (through 2000), then as a regional leader of Internal Audit Services (through 2010), and finally as Managing Partner of Strategic Development for PwC’s Risk Assurance practice (through his retirement in 2014). Mr. Cappell has worked with public companies in a variety of industries, including consumer and industrial products, financial services and entertainment. He has advised public company audit committees on diverse topics and has served as the de facto internal audit director at several companies. Mr. Cappell is a member of AICPA and the New York State Society of CPAs. Mr. Cappell has a B.A. in Economics from Yeshiva University and an M.B.A. in Finance from the NYU Stern School of Business.

Martin Goldman, M.D. – Director
Dr. Goldman began serving on our Board in June 2017.  He is a chaired professor, Vice Chair for Education, Program Director of the Academic Program Training and Associate Director of Cardiology at a major academic medical center in New York City . He also has a large referral practice in clinical cardiology.  He holds a certifications in internal medicine and cardiovascular disease from the American Board of Internal Medicine.  Dr. Goldman received his M.D. at Albert Einstein College of Medicine and completed his internship and residency in Internal Medicine at Brigham and Women’s Hospital at Harvard Medical School . He did his cardiology fellowship and advanced cardiac imaging at Mount Sinai, NYC. He has published over 200 scientific articles.

William Natbony – Director
Mr. Natbony has served on our Board since June 2017.  He is the CEO and Executive Chairman of the Zander Ridge Group, a private family office, and previously was the CEO and Executive Chairman of Tigris Group Inc., a diversified multi-billion dollar family office. Prior to joining Tigris, Mr. Natbony was a senior partner at the international law firm of Katten Muchin Rosenman LLP and was listed in Leading Lawyers in America, New York Super Lawyers and Best Lawyers in America. Mr. Natbony currently holds directorships at Gabriel Resources Ltd., a resources company listed on the Toronto Stock Exchange, Electrum Ltd., a privately-held gold exploration company, Sunshine Silver Mining & Refining Corporation, a privately-held silver exploration and development company, and Panthera Corp. and the Orianne Society, charities that support wildlife conservation. Mr. Natbony holds a J.D. and an LL.M. (in Taxation) from New York University and has been a member of the New York Bar since 1976.

Jeffrey Paley, M.D. – Director
Dr. Paley joined our Board of Directors in June 2017. Dr. Paley has been an active clinician and consultant in the healthcare industry for the past 18 years, during which time Dr. Paley has consulted for over 30 analysts and portfolio managers in the biotechnology, pharmaceutical, specialty pharmaceutical and medical technology arenas, reviewing the clinical, preclinical and regulatory pedigrees of numerous therapeutics and devices. Prior to his work for the buy-side, Dr. Paley consulted directly for several biotechnology and specialty pharmaceutical companies. Dr. Paley founded Access Medical Associates in 2003, after spending five years on the full-time academic faculty of Weill Cornell Medical College, where he served as a Director of Clinical Research at the Cornell Internal Medicine Associates. At Weill Cornell, Dr. Paley was a Principal or Co-Principal Investigator on several studies of diabetes, hypertension, and cholesterol disorders, including the landmark ACCORD study of intensive hyperglycemia, hypertension and hyperlipidemia management. He has served as a Director of Kellbenx, Retrophin and Remote Radiology Inc. and currently serves as a Director of Avenue Therapeutics, Inc., Kalytera Therapeutics, Inc. and Immune Pharmaceuticals, Inc.  Dr. Paley trained at Harvard Medical School and completed a residency in Internal Medicine at Massachusetts General Hospital. Dr. Paley has been selected to serve on our Board of Directors based on his experience, including his experience in medicine and clinical trials and in serving as a director of other public companies.